Kirn David sold $125K of FDMT
Kirn David (See Remarks) sold 12,415 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $10.05 ($0.12M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note insider selling, but the filing does not introduce new company fundamentals or guidance.
What to watch
Insider sales can be driven by diversification, taxes, or scheduled plans; without additional context, directional inference is weak.
Background
The article is an SEC Form 4 insider transaction disclosure for 4D Molecular Therapeutics, Inc.
Ticker impact
Kirn David filed an open-market sale of 12,415 FDMT shares at $10.0461 on 2026-08-03 under a 10b5-1 plan.
Likely limited near-term impact; any effect is more about sentiment than new fundamentals.
Form 4 reports an insider transaction size and price, but provides no new operational, financial, or regulatory information about FDMT.
Market effects
No clear sector read-through from a single insider sale.
None indicated.
None indicated.
Counterpoint
The sale may be purely planned liquidity under a 10b5-1 plan, so it may not signal reduced confidence.
Key entities
- issuer4D Molecular Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderKirn David
Officer and director who sold shares under a 10b5-1 plan.
